Cialis vs Alprostadil (Caverject/MUSE): Head-to-Head Efficacy Compared

Why These Two Drugs Get Compared

Tadalafil and alprostadil represent the two major pharmacologic strategies for erectile dysfunction (ED): oral PDE5 inhibition and direct prostaglandin E1-mediated smooth muscle relaxation. They work through completely different mechanisms. Tadalafil blocks phosphodiesterase type 5 to amplify nitric oxide signaling during sexual stimulation [1]. Alprostadil acts as a synthetic prostaglandin E1 analog that directly relaxes corporal smooth muscle, independent of nerve input or nitric oxide availability [2].

This distinction matters clinically. Men who fail PDE5 inhibitors due to severe vascular disease, post-prostatectomy nerve damage, or diabetes-related neuropathy often respond to alprostadil because it does not require intact erectile nerve pathways. The American Urological Association (AUA) guidelines position PDE5 inhibitors as first-line pharmacotherapy and intracavernosal injection (ICI) with alprostadil as second-line for men who do not respond to or cannot tolerate oral agents [3]. MUSE (medicated urethral system for erection) occupies a middle position: less invasive than injection, but also less effective.

No large, multicenter, randomized controlled trial has directly compared tadalafil to alprostadil. The evidence base consists of separate key trials for each drug, crossover studies with mixed PDE5 inhibitor cohorts, and retrospective analyses. All efficacy comparisons must be interpreted as indirect, drawn from different study populations and endpoints.

Tadalafil Efficacy: What the Key Data Show

Tadalafil at 20 mg on-demand produced a mean 7.9-point improvement on the International Index of Erectile Function (IIEF) erectile function domain score compared to placebo in the key trial by Brock et al. (N=1,112) [1]. That trial enrolled men across a broad severity spectrum and reported successful intercourse attempts in 73% of encounters at the 20 mg dose, versus 32% with placebo.

The 36-hour duration of action sets tadalafil apart from sildenafil and vardenafil. A 2004 pooled analysis of five randomized trials (N=2,159) found that tadalafil 20 mg improved IIEF scores by 6.5 to 8.6 points across mild, moderate, and severe ED subgroups [4]. Daily tadalafil at 5 mg was later approved for both ED and benign prostatic hyperplasia (BPH), providing continuous erectile readiness without timing a dose to sexual activity. In the daily dosing studies, 67.2% of intercourse attempts were successful at 5 mg daily versus 31.6% for placebo [5].

For men with diabetes, a population with notoriously treatment-resistant ED, tadalafil 20 mg achieved successful intercourse in 64% of attempts versus 25% for placebo [6]. Post-radical prostatectomy data are less encouraging: bilateral nerve-sparing surgery patients showed a 52% intercourse success rate at 20 mg, while non-nerve-sparing patients dropped to approximately 19% [7].

Alprostadil Injection (Caverject) Efficacy

Intracavernosal alprostadil is the most effective single-agent pharmacotherapy for ED. The landmark Linet and Ogrinc trial published in the New England Journal of Medicine (N=296) reported that 87% of injections at optimized doses produced erections rated adequate for intercourse by investigators, and 70% of participating men achieved functional erections across the dose-titration phase [2].

That 70% figure is particularly significant because it includes men with severe vasculogenic and neurogenic ED. A separate European multicenter study (N=683) found that 82.4% of men achieved erections sufficient for penetration at doses between 5 and 20 mcg [8]. Duration of erection averaged 47 to 81 minutes depending on dose. Among men who had previously failed oral agents, intracavernosal alprostadil still produced adequate erections in 68-85% of cases across multiple retrospective series [9].

The dose range is wide. Some men respond to 2.5 mcg; others require the maximum recommended 40 mcg. Office-based dose titration is mandatory before home use to minimize priapism risk. The AUA guidelines recommend starting at 2.5 mcg for neurogenic ED and 10 mcg for vasculogenic ED, then titrating upward in 5-10 mcg increments [3].

Priapism (erection lasting >4 hours) occurred in 1-3% of injections across clinical trials. Penile fibrosis developed in approximately 7-8% of long-term users [2].

MUSE (Intraurethral Alprostadil) Efficacy

MUSE delivers alprostadil as a pellet inserted into the urethra via a single-use applicator. Its efficacy falls well below intracavernosal injection. The key MUSE trial (N=1,511) reported that 65.9% of men achieved erections sufficient for intercourse in the clinic, but only 50.4% of at-home administrations resulted in successful intercourse [10].

That gap between in-clinic and at-home success rates is consistent across MUSE literature. Absorption through the urethral mucosa is less predictable than direct intracavernosal delivery. Penile pain occurred in 32.7% of patients and urethral burning in 12.4% [10]. Hypotension and dizziness affected 3.3% and 1.7% respectively.

For many clinicians, MUSE occupies a narrow niche: men who refuse self-injection but have failed oral therapy. Its at-home success rate of approximately 50% places it between PDE5 inhibitors and intracavernosal injection on the efficacy continuum.

Indirect Efficacy Comparison: Tadalafil vs Alprostadil

Because no direct head-to-head trial exists, the most honest comparison aligns published response rates by ED severity and prior treatment failure.

In PDE5-naive men with mild-to-moderate ED: Tadalafil 20 mg on-demand achieves intercourse success rates of 68-81%. Intracavernosal alprostadil achieves 82-87% at optimized doses. Both are highly effective in this population, but alprostadil carries needle burden and penile fibrosis risk that make it inappropriate as first-line.

In men with diabetes-associated ED: Tadalafil 20 mg produces a 64% intercourse success rate. Alprostadil injection retains ~70-80% efficacy even in diabetic subgroups, reflecting its nerve-independent mechanism.

In post-prostatectomy ED: Tadalafil efficacy drops significantly in non-nerve-sparing cases (19%). Alprostadil injection maintains 60-67% response rates regardless of nerve status because it acts directly on smooth muscle [9].

In PDE5 inhibitor non-responders: This is alprostadil's primary clinical role. Approximately 30-35% of men do not respond adequately to any PDE5 inhibitor. Among these non-responders, intracavernosal alprostadil rescues 68-85% [9]. MUSE rescues approximately 40-50%.

A 2006 crossover study by Vardi et al. found that among men who failed sildenafil 100 mg, 83.3% responded to intracavernosal alprostadil [11]. While this study used sildenafil rather than tadalafil as the comparator, the finding supports the principle that injectable alprostadil addresses a physiologically distinct patient population.

Onset, Duration, and Dosing Practicalities

The two drugs demand very different approaches to sexual planning. Tadalafil's 36-hour window allows men to take a dose Friday evening and retain efficacy through Sunday morning. Peak plasma concentration occurs at approximately 2 hours, but clinically meaningful onset begins within 30-45 minutes for many patients [12]. Daily 5 mg dosing eliminates timing concerns entirely and provides continuous BPH symptom relief as a secondary benefit.

Alprostadil injection works in 5 to 20 minutes. That rapid onset is an advantage for men who want a predictable, time-limited response. The erection typically lasts 30-60 minutes, though durations up to 2 hours occur at higher doses. Men inject directly into the lateral aspect of the penile shaft using a 27- to 30-gauge needle. The injection itself is described as causing mild discomfort, rated 2-3 on a 10-point pain scale in most surveys [8].

MUSE requires 10-30 minutes for onset. Men must remain standing or walking for 10 minutes after insertion to improve drug absorption. The penile constriction band included with MUSE improves efficacy by limiting venous drainage.

Tadalafil is a pill. That simplicity matters. Adherence data consistently show higher long-term continuation rates with oral therapy than with intracavernosal injection: approximately 50-70% of men continue PDE5 inhibitors at one year versus 40-60% for ICI [13].

Side Effect Profiles

Tadalafil's most common adverse effects are headache (14.5%), dyspepsia (12.3%), back pain (6.5%), myalgia (5.7%), and nasal congestion (4.3%) [1]. The back pain and myalgia are relatively unique to tadalafil among PDE5 inhibitors and relate to PDE11 cross-reactivity. All effects are typically mild to moderate and resolve within 24-48 hours. Tadalafil is contraindicated with nitrate medications due to risk of severe hypotension [12].

Alprostadil injection causes penile pain in 29-50% of users, ranging from mild aching to moderate burning at the injection site [2]. Penile fibrosis or plaque formation occurs in 7-8% of long-term users. Prolonged erection (>4 hours) requiring medical intervention occurs in 1-3%. Hematoma at the injection site is common but clinically insignificant.

"The risk of priapism with intracavernosal alprostadil is low but not trivial, and patients must be educated to seek emergency treatment if an erection persists beyond four hours," per the AUA guideline on management of erectile dysfunction [3].

MUSE avoids needle-related complications but produces urethral pain in 24-33% and dizziness or hypotension in up to 5% [10]. Partner vaginal burning has been reported in 5.8% of female partners, likely from transurethral drug transfer.

Cost and Access Considerations

Generic tadalafil is now widely available in the United States. A 30-tablet supply of generic tadalafil 20 mg costs approximately $15-60 at major retail pharmacies with discount coupons, making it one of the least expensive ED treatments available. Brand-name Cialis runs $400-500 for the same quantity without insurance.

Caverject Impulse (alprostadil for injection) costs approximately $60-85 per single-dose syringe, and most men use 2-4 injections per month. The compounded alternative, trimix (alprostadil + papaverine + phentolamine), is significantly less expensive per dose ($2-8 per injection from compounding pharmacies) and is the most commonly prescribed ICI formulation in clinical practice, though it is not FDA-approved as a fixed combination [14].

MUSE costs approximately $35-60 per individual applicator. At 8 applications per month, this totals $280-480 monthly.

Insurance coverage varies. Most commercial plans cover generic tadalafil with quantity limits (typically 6-12 tablets per month). Alprostadil injection coverage is less consistent and often requires prior authorization documenting PDE5 inhibitor failure.

Who Should Use Which Drug

The decision between tadalafil and alprostadil is rarely ambiguous. Start with tadalafil. The AUA, European Association of Urology (EAU), and International Society for Sexual Medicine (ISSM) all recommend PDE5 inhibitors as first-line pharmacotherapy for ED [3].

"PDE5 inhibitors are first-line therapy for erectile dysfunction. Second-line therapies such as intracavernosal injection should be offered when PDE5 inhibitors are ineffective, contraindicated, or not tolerated," states the 2018 AUA guideline [3].

Move to alprostadil injection when tadalafil and at least one other PDE5 inhibitor have been tried at maximum dose for a minimum of 4-6 attempts each without adequate response. Do not declare PDE5 failure after a single attempt. Sexual performance anxiety, improper timing relative to food intake, and inadequate sexual stimulation are correctable factors that can mimic pharmacologic failure.

Consider MUSE only for men who refuse self-injection and accept its lower efficacy. Its role has diminished as generic PDE5 inhibitors have become affordable and trimix has grown more accessible through compounding pharmacies.

For post-prostatectomy patients with non-nerve-sparing surgery, consider early intracavernosal alprostadil rather than prolonged PDE5 inhibitor trials, given the physiologic implausibility of PDE5 response without intact cavernous nerves.

Combination Therapy

Some clinicians prescribe low-dose intracavernosal alprostadil alongside daily tadalafil 5 mg in men with partial responses to either agent alone. A small study (N=32) by McMahon et al. found that combination therapy improved IIEF erectile function domain scores by an additional 3.2 points over alprostadil monotherapy [15]. This approach is off-label and requires careful cardiovascular screening, but it reflects real-world practice patterns among sexual medicine specialists.

Daily tadalafil 5 mg has also been studied as a "rehabilitation" strategy following radical prostatectomy, with the hypothesis that continuous PDE5 inhibition preserves endothelial function during the nerve recovery window. The REACTT trial (N=423) found that daily tadalafil 5 mg for 9 months improved unassisted erectile function recovery at 9 months (25.2% vs. 14.2% for placebo), though the benefit narrowed at 12-month follow-up after drug washout [16].

Alprostadil injection remains the single most effective drug for penile rehabilitation after prostatectomy, achieving functional erection rates of 67% even when initiated within 4 weeks of surgery [17].